Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017111045) TLR INHIBITORY OLIGONUCLEOTIDES AND THEIR USE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/111045 International Application No.: PCT/JP2016/088418
Publication Date: 29.06.2017 International Filing Date: 22.12.2016
IPC:
C12N 15/117 (2010.01) ,A61K 31/7088 (2006.01) ,A61P 37/02 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
117
Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
Applicants:
SBI BIOTECH CO., LTD. [JP/JP]; 1-6-1, Roppongi, Minato-ku, Tokyo 1066018, JP
Inventors:
ESASHI Eiji; JP
ISHIDA Koji; JP
HOSOZAWA Takumi; JP
OKUYAMA Megumi; JP
KOTAKI Ayumi; JP
Agent:
ASAMURA PATENT OFFICE,P.C.; Tennoz Central Tower, 2-2-24 Higashi-Shinagawa, Shinagawa-ku, Tokyo 1408776, JP
Priority Data:
2015-25500825.12.2015JP
Title (EN) TLR INHIBITORY OLIGONUCLEOTIDES AND THEIR USE
(FR) OLIGONUCLÉOTIDES INHIBITEURS DE TLR ET LEUR UTILISATION
Abstract:
(EN) The inhibitory oligonucleotides with partial phosphorothioation with reduced toxicity strongly block NF-kB activation induced by TLR9 agonists and TLR7/8 agonists. The production of proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFa), is inhibited by the inhibitory-oligonucleotides. Interferon (IFN) production from human PBMC induced by TLR9 agonist is prevented by the inhibitory-oligonucleotides. These oligonucleotides can be used as a remedy for the treatment of immune-mediated disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes and inflammatory cytokine-mediated inflammatory disease.
(FR) Les oligonucléotides inhibiteurs présentant une phosphorothioation partielle à toxicité réduite bloquent fortement l'activation du NF-kB induite par des agonistes de TLR9 et des agonistes de TLR7/8. La production de cytokines pro-inflammatoires, telles que l'interleukine-6 (IL-6) et le facteur de nécrose tumorale alpha (TNFa) est inhibée par les oligonucléotides inhibiteurs. La production d'interféron (IFN) à partir de CMSP humaines induite par un agoniste de TLR9 est empêchée par les oligonucléotides inhibiteurs. Ces oligonucléotides peuvent être utilisés comme remède pour le traitement de troubles à médiation immunitaire, tels que la polyarthrite rhumatoïde, le lupus érythémateux systémique (LES), le sepsis, les syndromes de dysfonctionnement organique multiple et une maladie inflammatoire médiée par des cytokines inflammatoires.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU2016375543CA3009154IL260193CN108431228KR1020180089531EP3394263
US20190008888